---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-026438"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2025-12-05T23:59:59+00:00"
generated_at: "2026-05-16T14:16:51.678518+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics issues $2.09M unsecured note, net proceeds $1.5M, weekly $70K payments

## Summary
- Principal amount $2,093,340; net proceeds ~$1,500,000 after $587,340 OID and $6,000 fees.
- Weekly payments of $69,778 start December 12, 2025; full prepay by Jan 4, 2026 reduces balance by $286,140.
- Note is unsecured, no interest unless default; subsidiary Airway Integrated Management guarantees obligations.
- Proceeds for working capital and general corporate purposes; no placement agent used.
- Lender Avondale Capital is affiliate of Streeterville Capital (prior senior secured loan from June 2025).

## SEC filing metadata
- accession: 0001493152-25-026438
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2025-12-05T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315225026438/0001493152-25-026438-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315225026438/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-026438
- JSON: https://secwatch.observer/filing/0001493152-25-026438.json
- Plain text: https://secwatch.observer/filing/0001493152-25-026438.txt

## Key facts
- Debt Financings
  Vivos Therapeutics, Inc. incurred loan of $2,093,340 with Avondale Capital, LLC at does not bear interest maturing not stated.
  - Instrument: loan
  - Principal: $2,093,340
  - Counterparty: Avondale Capital, LLC
  - Rate: does not bear interest
  - Maturity: not stated
  - Event: incurrence
  source text: On December 5, 2025, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a Note Purchase Agreement (the “ Note Purchase Agreement ”) with from Avondale Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to Lender a Promissory Note (the “ Note ”) in the original principal amount of $2,093,340
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315225026438/0001493152-25-026438-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.